CN107937453B - Preparation method and antibacterial activity application of dichloro-substituted II-type halogenated polyketone compound - Google Patents
Preparation method and antibacterial activity application of dichloro-substituted II-type halogenated polyketone compound Download PDFInfo
- Publication number
- CN107937453B CN107937453B CN201711171668.2A CN201711171668A CN107937453B CN 107937453 B CN107937453 B CN 107937453B CN 201711171668 A CN201711171668 A CN 201711171668A CN 107937453 B CN107937453 B CN 107937453B
- Authority
- CN
- China
- Prior art keywords
- strain
- dichloro
- substituted
- preparation
- acetone
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P17/00—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms
- C12P17/18—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms containing at least two hetero rings condensed among themselves or condensed with a common carbocyclic ring system, e.g. rifamycin
- C12P17/181—Heterocyclic compounds containing oxygen atoms as the only ring heteroatoms in the condensed system, e.g. Salinomycin, Septamycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Wood Science & Technology (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Zoology (AREA)
- General Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The application discloses a preparation method of dichloro-substituted halogenated II type polyketide zunyiminycin A, which is derived from a secondary metabolite of Streptomyces sp.FJS31-2 strain (strain preservation number: CGMCC4.7321), and is determined by activating, expanding culture and separation of the strain and finally carrying out structural identification. Can be used for treating gram-positive bacteria such as Staphylococcus aureus (MRSA) and its drug-resistant bacteria, Staphylococcus epidermidis, Bacillus subtilis, etc.; the composition is applied to the treatment of gram-negative bacteria such as Escherichia coli (ESBL) generating extended-spectrum beta-lactamase, proteus, Brucella and other infectious diseases; can be used for treating fungal infection diseases such as Candida albicans.
Description
Technical Field
The invention relates to the technical field of microorganisms, in particular to a preparation method of dichloro-substituted II-type halogenated polyketone compounds and an application of antibacterial activity, and particularly relates to a preparation method of dichloro-substituted halogenated II-type polyketone compounds zunyimycin A and an application of antibacterial activity.
Background
Natural products from streptomyces often have good biological activity and drug-forming potential, and are important sources of antibiotics. However, with the abuse of antibiotics, the appearance of a plurality of 'super bacteria' brings huge challenges to the treatment of diseases such as pathogenic bacteria infection and the like in clinic, and some super bacteria have the phenomenon of no medicine and no medical treatment. In view of the current increasingly severe antibacterial situation, the research and development of antibiotics is increased, and the exploration and research of new antibiotics become urgent matters, and are also effective ways for solving the problem of antibiotic resistance.
The halogenated natural product from streptomycete has the characteristics of novel structure, good activity and the like. Such as: chlorinated polyketone neocarzillin a having antileukemic activity; BE-19412A and its methylation product with inhibitory effect on mouse tumor cells; polyketone chinikomicins A with inhibition effect on different tumor cells of human body; chlorophenazine having bactericidal action against multi-drug resistant mycobacterium tuberculosis. In addition, the clinical anti-infective vancomycin, teicoplanin and new antibiotic drugs dalbavancin, oritavancin and tedizolid which are approved to be marketed by the FDA in the U.S. in 2014 and are all halogenated natural products.
In the earlier stage of the subject group, a strain named Streptomyces sp.FJS31-2 (the strain preservation number is CGMCC4.7321) is separated and identified from Sanjing mountain soil of special habitat Vaskrita of Guizhou, and through secondary metabolite research, the compounds of the novel chlorinated polyketone series, namely the compound of zunyiminycin A, zunyiminycin B and zunyiminycin C, are obtained through separation and identification, such as a halogenated II type polyketone antibiotic compound disclosed in Chinese patent CN106167495A, a preparation method and application thereof, the halogenated II type polyketone antibiotic compound is the compound of zunyiminycin A,
zunyimycin A structural formula
However, due to the defects of the preparation method, the yield is small, the yield is low, and only the activity of the drug-resistant staphylococcus aureus is performed because the yield is very small (about 7mg of each compound).
Disclosure of Invention
The invention aims to provide a preparation method of dichloro-substituted II-type halogenated polyketone compounds so as to obtain higher yield and research other antibacterial activities.
A preparation method of dichloro-substituted II-type halogenated polyketone compounds is characterized by comprising the following steps: step one, activating a strain: the preserved Streptomyces sp.FJS31-2 strain is taken out from a refrigerator at the temperature of minus 80 ℃, the preservation number of the strain is CGMCC NO.4.7321, the preservation date is 2016, 6 and 2 days, the preservation unit is the common microorganism center of China general microbiological culture Collection center, and the preservation address is No. 3 Siro No. 1 Hospital of North Chen of the sunward area in Beijing. During activation: digging spores of the strains by using an aseptic inoculating loop, cross-streaking and inoculating the spores on a flat plate of a basic culture medium, standing and culturing for 3d at 28 ℃, selecting single colonies, subculturing to the third generation, and then carrying out amplification culture;
step two, fermentation culture of fermentation products: selecting an improved GYD solid culture medium for fermentation culture, adding agar powder into the culture medium, standing at 28 ℃ for 17d, mashing the thallus together with the culture medium, adding ethyl acetate for extraction twice, combining the extract, and concentrating under reduced pressure to obtain a fermentation product;
step three, purification and separation of fermentation products: a. dissolving the fermentation product with acetone solvent, mixing with silica gel powder, and purifying with chloroform-acetone; 30: 1; 15: 1; 10: 1; 5: 1; 2: 1; pure acetone, sequentially carrying out 7 gradient elutions and collecting eluent, carrying out rotary evaporation and reduced pressure recovery on the eluent, developing the eluent by using a developing agent, combining points with 365nm fluorescence yellow-green color, 8% sulfuric acid ethanol yellow color and 0.5 migration value (Rf), and weighing to obtain F5;
b. f5 is separated by normal phase silica gel column chromatography, after the component F5 is dissolved in acetone solvent, the mixture is mixed with silica gel powder according to the ratio of 6:1 by adopting petroleum ether-acetone; 4: 1; sequentially eluting 3 gradient eluates in sequence at ratio of 2:1, collecting eluting solvent, performing rotary evaporation and reduced pressure recovery of the eluting solvent, developing with developing agent, mixing 365nm fluorescence yellow-green, 8% sulphuric acid ethanol yellow, migration value (Rf) at 0.5, mixing, and weighing to obtain F5-1;
c. dissolving F5-1 in acetone, scraping silica gel powder showing yellow-green fluorescence under 365nm fluorescence by adopting a thin-layer chromatography method, uniformly grinding the scraped silica gel powder, filling the ground silica gel powder into a separation column, eluting by adopting acetone, and recovering an acetone solvent to obtain the zunyiminycin A compound.
Compared with the prior art, the preparation method of the invention can effectively improve the reproductive capacity of the strain and accelerate the metabolism of the strain by compounding the fermentation base components when the initial spore amount is the same, so as to obtain the zunyiminycin A compound which is about 6 times that of the prior art.
Further, the preparation method of the dichloro-substituted II-type halogenated polyketone compound comprises the steps of soaking 4g/L of glucose, 4g/L of malt extract, 4g/L of yeast powder, 2g/L of calcium carbonate, 0.5mL of trace element premix liquid and 10g/L of absolute ethyl alcohol in the improved GYD solid culture medium for 24 hours of humic acid, adding deionized water to a constant volume of 1L, and carrying out high-pressure sterilization at 121 ℃ for 30 minutes.
The microelement premix is prepared from ZnSO 4.7H2O 1-2 parts, FeSO 4.7H2O 1-2 parts, MnCl 2.4H2O 1-2 parts, CuSO 4.5H2O 1-2 parts, Na2B4O 4.10H2O 1-2 parts and (NH4)6MO 7.4H2O 1-2 parts, and the volume of the microelement premix is adjusted to 1L by double distilled water.
Further, the developing solvent is petroleum ether: acetone ═ 2:1, chloroform: acetone ═ 5:1 or chloroform: methanol 10: 1.
use of dichloro-substituted halogenated polyketones of type II for their activity against gram-positive bacteria. The gram-positive bacteria include staphylococcus epidermidis and bacillus subtilis.
Use of dichloro-substituted halogenated polyketones of type II for their activity against gram-negative bacteria. The gram-negative bacteria include Escherichia coli, Proteus, and Brucella which produce extended-spectrum beta-lactamases.
Use of dichloro-substituted halogenated polyketones of type II for antifungal activity. The fungus is Candida albicans.
Drawings
FIG. 1 is a diagram showing the separation and purification of Zunyimycin A;
FIG. 2 is a graph of Zunyimycin A activity against Staphylococcus epidermidis;
FIG. 3 is a graph showing the activity of Zunyimycin A against Bacillus proteus;
FIG. 4 is a graph of Zunyimycin A activity against Brucella;
FIG. 5 is a graph of Zunyimycin A activity against Candida albicans;
FIG. 6 is a graph of Zunyimycin A activity against Bacillus subtilis;
FIG. 7 is a graph of Zunyimycin A anti-MRSA activity;
FIG. 8 is a graph of Zunyimycin A anti-ESBL activity.
Detailed Description
The present invention will be described in further detail below by way of specific embodiments:
preparation method of dichloro-substituted II-type halogenated polyketone compounds
Step one, activation of Streptomyces sp.FJS31-2 strain
Taking out the strain preserved on the glycerol slant from a refrigerator at minus 80 ℃, digging spores of 1-ring strain Streptomyces sp, FJS31-2 by using an aseptic inoculating loop, cross-streaking and inoculating the spores to a basal medium plate with the diameter of 11cm, standing and culturing for 3d at 28 ℃, and picking single bacterial colony to pass to the third generation for amplified culture.
Step two, fermentation culture of fermentation product
Streptomyces sp.FJS31-2 strain is cultured by fermentation in an improved GYD solid culture medium, 150mL of fermentation culture medium is bottled in 500 mL triangular flask, and agar powder is added into each flask according to the mass of the agar powder and 1.8% of the volume of the fermentation culture medium. Inoculating the activated strain with the amount of 1 × 1cm2 on the culture plate per bottle, standing at 28 deg.C for 17d, mashing the strain and culture medium, extracting with ethyl acetate twice at 130rpm for 24 hr, mixing extractive solutions, and concentrating at 40 deg.C under reduced pressure to obtain fermented product. The above operations were repeated, and a total of 38g of fermentation product was obtained by combining 100L of fermentation culture.
The formula of the improved GYD culture medium is as follows: 4g/L of glucose, 4g/L of malt extract, 4g/L of yeast powder, 2g/L of calcium carbonate, 0.5mL of trace element premix, 10g/L of absolute ethyl alcohol, humic acid soaked for 24h, deionized water added to the solution to reach a constant volume of 1L, and autoclaving at 121 ℃ for 30 min.
The trace element premix liquid: ZnSO4 & 7H2O 2g, FeSO4 & 7H2O 2g, MnCl2 & 4H2O 2g, CuSO4 & 5H2O 2g, Na2B4O4 & 10H2O 2g and (NH4)6MO7 & 4H2O 2g, and prepared by using double distilled water to a constant volume of 1L.
Step three, purifying and separating the fermentation product
a. Dissolving 32g of fermentation product by using acetone solvent, uniformly mixing the fermentation product with silica gel according to the mass ratio of about 1:1.5 (namely adding 48g of 100-200-mesh silica gel powder into 32g of fermentation product), and volatilizing the solvent to obtain a river sand-shaped sample which is used as a sample for loading on a column; weighing 1200g of 100-200-mesh silica gel powder and a chloroform solvent, uniformly mixing (bubbles cannot be generated in the process) the silica gel powder and the chloroform solvent, putting the mixture into a separation column with the length of 975mm and the inner diameter of 120mm, slowly sinking the silica gel powder until the silica gel powder does not sink, adding an upper column sample, and adopting chloroform-acetone [ pure chloroform ]; 30: 1; 15: 1; 10: 1; 5: 1; 2: 1; pure acetone ], sequentially eluting by 7 gradients, eluting by 3-4 (about 7.2L-9.6L of elution solvent per column volume) columns by each gradient, collecting 80 parts of elution solvent per 1000mL, recovering by a rotary evaporator under reduced pressure, adding 10mL of acetone to dissolve the solvent, transferring the solvent into a penicillin bottle with the specification of 20mL, performing thin layer chromatography (TCL) spotting, and performing thin layer chromatography (petroleum ether): acetone ═ 2:1, chloroform: acetone ═ 5:1 or chloroform: methanol 10:1, developing with a developing agent, observing whether the fluorescence is 254nm or 365nm under a conventional ultraviolet visible light analyzer, and developing with a coloring agent developing with 8% sulfuric acid ethanol; the 365nm fluorescence yellow-green color and the 8% sulfuric acid ethanol yellow color were combined, and the mobility value (Rf) was at 0.5 point, and after combining, F53.124g was obtained by weighing.
b. F53.124g is further purified and separated by normal phase silica gel column chromatography. Uniformly mixing 3.124g of dissolved components of the acetone solvent and silica gel according to the mass ratio of about 1:1.5 (namely 3.124g of fermentation product is added with 4.7g of 100-200-mesh silica gel powder), and obtaining a river sand-shaped sample after the solvent is volatilized, wherein the sample is used as a sample for loading on a column; weighing 140 g of 100-one 200-mesh silica gel powder and petroleum ether: acetone (6: 1) (no bubbles generated during the process) is loaded into a separation column with a length of 975mm and an inner diameter of 50mm, silica gel powder is slowly sunk until no more sinking, and a sample is loaded into the column, and petroleum ether-acetone [6: 1; 4: 1; 2:1], sequentially eluting by 3 gradients, wherein each gradient elutes 4-5 (about 1L-1.2L of elution solvent per column volume) columns, collecting 40 parts of elution solvent per 100mL, adding 10mL of acetone after decompression and recovery of each part by a rotary evaporator, dissolving, transferring into a penicillin bottle with the specification of 20mL, performing thin layer chromatography (TCL) spotting, and performing petroleum ether: acetone ═ 2:1, chloroform: acetone ═ 5:1 or chloroform: methanol 10:1, developing with a developing agent, observing whether the fluorescence is 254nm or 365nm under a conventional ultraviolet visible light analyzer, and developing with a coloring agent developing with 8% sulfuric acid ethanol; the 365nm fluorescence was combined to give a yellowish green color, the 8% ethanol sulfate was combined to give a yellow color, and the mobility value (Rf) was at a point of 0.5, and after combining, F5-391 mg was weighed.
c. F5-191 mg of component, after dissolving with acetone, spot-counting (plate specification: 20 cm. times.20 cm) thin layer chromatography plate with sample loading of 45 mg/block by thin layer chromatography (TCL) method, preparing chloroform: acetone: and (2) dropping 140mL of developing agent in a ratio of 6:1:1, pouring the developing agent into a developing cylinder, putting a thin-layer chromatography plate into the developing cylinder, taking out the plate when the solvent is about 0.5cm away from the edge of the plate, volatilizing the solvent, observing under 365nm fluorescence, scraping off silica gel powder showing yellow-green fluorescence under 365nm fluorescence, uniformly grinding the scraped silica gel powder, putting the silica gel powder into a separation column, eluting by using acetone, and recovering an acetone solvent machine to obtain 41mg of the zunyiminycin A compound.
Application of Zunyimycin A in antibacterial activity
(1) The test strains were: staphylococcus Aureus (MRSA), Bacillus subtilis, Brucella, Staphylococcus epidermidis, Proteus, Escherichia coli (ESBL) producing extended-spectrum beta-lactamase, and Candida albicans.
(2) Culture medium: MH (A) culture medium, weighing MH (A) culture medium 36.5g and distilled water 1L, mixing well, and autoclaving at 121 deg.C for 15 min. The medium was poured into plates in a clean bench, approximately 20mL each. The culture dish is placed in an oven at 30 ℃ for 24h, whether bacteria grow or not is observed, and the culture dish can be used in an aseptic mode.
(3) Strain activation: taking out the test strains preserved on the glycerol inclined plane from a refrigerator at the temperature of minus 80 ℃, digging 1 ring of each test strain by using a sterile inoculating loop, cross-streaking and inoculating the test strains on an MH (A) culture medium plate with the diameter of 11cm, standing and culturing for 1d at the temperature of 37 ℃, and picking single colonies and subculturing to a third generation.
(4) Preparation of a solution of compound Zunyimycin A: zunyimycin A3 mg was weighed out and dissolved in 1mL DMSO solution to make the solution clear without turbidity.
(4) The antibacterial activity was measured by the agar diffusion method: firstly, preparing a suspension of test bacteria with the concentration of 10-6 or 10-7 by using distilled water; secondly, the suspension is poured into MH (A) culture medium to ensure that the surface coating is uniform; thirdly, punching a plurality of small holes with the diameter of 8mm on MH (A) culture medium coated with test bacteria, and respectively inoculating 100uL of Zunyimycin A solution and a control in the small holes; fourthly, putting the culture dish into an incubation thermostat at 37 ℃ for culturing for 24 hours, and taking out the culture dish to measure the diameter of the inhibition zone.
Sixth, application example
An agar diffusion method is adopted to determine the antibacterial activity test of Zunyimycin A, and staphylococcus aureus (MRSA), bacillus subtilis, Brucella, staphylococcus epidermidis, proteus, escherichia coli (ESBL) producing extended-spectrum beta-lactamase and candida albicans are taken as test bacteria, and DMSO is taken as a negative control. The results show that: zunyimycin A has a good inhibitory effect on staphylococcus aureus (MRSA), bacillus subtilis, brucella, staphylococcus epidermidis, proteus, escherichia coli (ESBL) producing extended-spectrum beta-lactamase, candida albicans and the like, the inhibition zone of Zunyimycin A is larger than 10mm, and the results are shown in FIGS. 2-8 and Table 1 in detail.
Table 1: zunyimycin A antibacterial activity detection result
Zunyimycin A Minimum Inhibitory Concentration (MIC)
(1) The test strains were: staphylococcus Aureus (MRSA), Bacillus subtilis, Brucella, Staphylococcus epidermidis, Proteus, Escherichia coli (ESBL) producing extended-spectrum beta-lactamase, and Candida albicans.
(2) Culture medium: MH (A) culture medium, weighing MH (A) culture medium 36.5g and distilled water 1L, mixing well, and autoclaving at 121 deg.C for 15 min. The medium was poured into plates in a clean bench, approximately 20mL each. The culture dish is placed in an oven at 30 ℃ for 24h, whether bacteria grow or not is observed, and the culture dish can be used in an aseptic mode.
(3) Strain activation: taking out the test strains preserved on the glycerol inclined plane from a refrigerator at the temperature of minus 80 ℃, digging 1 ring of each test strain by using a sterile inoculating loop, cross-streaking and inoculating the test strains on an MH (A) culture medium plate with the diameter of 11cm, standing and culturing for 1d at the temperature of 37 ℃, and picking single colonies and subculturing to a third generation.
(4) Preparation of a solution of compound Zunyimycin A: prepare 512 mug/mL solution and filter with microporous membrane for standby.
(5) Preparing a bacterial suspension: activating the strain to be detected for three generations, injecting normal saline into a slant culture medium in a super clean bench, and lightly scraping the bacterial colony by using an inoculating loop. And pouring the bacterial liquid into a 50ml triangular flask to ensure that the bacterial liquid is fully and uniformly mixed, and measuring by using a turbidimeter to prepare a Mycoleptodonoides concentration bacterial suspension.
(6) MIC determination: firstly, the method comprises the following steps: add MH broth in 96 well plates; secondly, the method comprises the following steps: adding 512 μ g/mL prepared medicinal liquid into the first hole, sufficiently blowing with a pipette to mix the medicinal liquid with the broth, sucking 100 μ L from the first hole, sufficiently blowing into the second hole, and mixing. Aspirate 100. mu.L of this to the eleventh well and discard. Two parallel rows of experiments were repeated for each drug; thirdly, the method comprises the following steps: adding 100 mu L of bacterial liquid into each hole; the fourth step: the 96-well plate is placed into a constant temperature incubator at 37 ℃ for 20 hours, and then the result is observed.
Table 2: minimum inhibitory concentration results
The foregoing is merely an example of the present invention, and common general knowledge in the field of known specific structures and characteristics of the embodiments has not been described in detail, so that a person of ordinary skill in the art can understand all the common technical knowledge in the field of the invention before the application date or the priority date, can know all the prior art in the field, and have the ability to apply routine experimentation before the application date. It should be noted that, for those skilled in the art, without departing from the structure of the present invention, several changes and modifications can be made, which should also be regarded as the protection scope of the present invention, and these will not affect the effect of the implementation of the present invention and the practicability of the patent. The scope of the claims of the present application shall be determined by the contents of the claims, and the description of the embodiments and the like in the specification shall be used to explain the contents of the claims.
Claims (1)
1. The application of dichloro-substituted II-type halogenated polyketone compounds is characterized in that: the dichloro-substituted II-type halogenated polyketone compound is used for preparing medicines for resisting deformation bacilli, Brucella and Escherichia coli generating extended-spectrum beta-lactamase, is a compound zunyiminycin A, and has the following structural formula:
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201711171668.2A CN107937453B (en) | 2017-11-22 | 2017-11-22 | Preparation method and antibacterial activity application of dichloro-substituted II-type halogenated polyketone compound |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201711171668.2A CN107937453B (en) | 2017-11-22 | 2017-11-22 | Preparation method and antibacterial activity application of dichloro-substituted II-type halogenated polyketone compound |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN107937453A CN107937453A (en) | 2018-04-20 |
| CN107937453B true CN107937453B (en) | 2022-04-15 |
Family
ID=61929762
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201711171668.2A Active CN107937453B (en) | 2017-11-22 | 2017-11-22 | Preparation method and antibacterial activity application of dichloro-substituted II-type halogenated polyketone compound |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN107937453B (en) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109182412A (en) * | 2018-10-11 | 2019-01-11 | 遵义医学院 | The preparation method and its antibacterial activity application of II type polymeric polyketone derivatives |
| CN109875995A (en) * | 2019-04-11 | 2019-06-14 | 延安大学 | II type polyketide of halogenation is inhibiting the application in Colon Cancer Cells |
| CN109999023B (en) * | 2019-04-11 | 2022-02-22 | 延安大学 | Application of halogenated II type polyketone antibiotics in inhibition of breast cancer cell proliferation |
| CN109875994A (en) * | 2019-04-11 | 2019-06-14 | 延安大学 | II type polyketide of halogenation is inhibiting the application in hepatoma cell proliferation |
| CN115054597B (en) * | 2022-06-30 | 2023-08-25 | 延安大学 | Application of halogenated type II polyketide in intervention of Alzheimer's disease |
| CN114903887B (en) * | 2022-06-30 | 2023-09-05 | 延安大学 | Application of halogenated type II polyketone antibiotics in enhancing immunity |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106167495A (en) * | 2016-06-03 | 2016-11-30 | 遵义医学院 | A kind of halogenation II type polyketide compound, preparation method and applications |
| CN106432262A (en) * | 2016-06-03 | 2017-02-22 | 遵义医学院 | Streptomyces-derived halogenated polyketide compound, preparation method and application |
-
2017
- 2017-11-22 CN CN201711171668.2A patent/CN107937453B/en active Active
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106167495A (en) * | 2016-06-03 | 2016-11-30 | 遵义医学院 | A kind of halogenation II type polyketide compound, preparation method and applications |
| CN106432262A (en) * | 2016-06-03 | 2017-02-22 | 遵义医学院 | Streptomyces-derived halogenated polyketide compound, preparation method and application |
Non-Patent Citations (3)
| Title |
|---|
| Molecular Genetic Characterization of an Anthrabenzoxocinones Gene Cluster in Streptomyces Sp. FJS31-2 for the Biosynthesis of BE-24566B and Zunyimycin Ale;Lü Yuhong等;《Molecules》;20160530;第21卷(第6期);第5-6页第4.1节 * |
| Zunyimycins B and C, New Chloroanthrabenzoxocinones Antibiotics against Methicillin-Resistant Staphylococcus aureus and Enterococci from Streptomyces sp. FJS31-2;Lü Yuhong等;《Molecules》;20170208;第22卷(第2期);表3 * |
| 链霉菌Streptomyces sp.FJS31-2产卤化二型聚酮类化合物的发酵条件优化;王荫荫等;《中国酿造》;20170125;第36卷(第1期);第67-68页第1.3部分、第67页第1.1.2段 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN107937453A (en) | 2018-04-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN107937453B (en) | Preparation method and antibacterial activity application of dichloro-substituted II-type halogenated polyketone compound | |
| Kumar et al. | Isolation, screening and partial purification of antimicrobial antibiotics from soil Streptomyces sp. SCA 7 | |
| CN107961233B (en) | Application of trichloro-substituted II-type halogenated polyketone compounds | |
| CN108017655B (en) | Monochloro-substituted II-type halogenated polyketone compound and preparation method and application thereof | |
| Omran et al. | Production, purification, and characterization of bioactive metabolites produced from rare actinobacteria Pseudonocardia alni | |
| CN109082445B (en) | Metabolite product of ginkgo endophytic fungi and application of metabolite product in antibiosis | |
| CN108093637A (en) | Novel bicyclic fat lanthiopeptin, preparation and the purposes as antimicrobial | |
| CN111778172B (en) | Streptomyces for producing antibacterial active compound and separation method and application thereof | |
| CN111088181B (en) | Bifidobacterium breve strain BK55 and application thereof in inhibiting clostridium difficile | |
| CN115536645B (en) | Compound Phomol B, preparation method thereof and application thereof in antibacterial drugs | |
| CN108102933B (en) | Streptomyces alboflavus strain and application thereof | |
| CN107488594B (en) | New penicillium and metabolite antacid A thereof | |
| CN111494364B (en) | Application of isopentenyl substituted phenol compound in resisting staphylococcus aureus and methicillin-resistant staphylococcus aureus | |
| CN114209742A (en) | Clostridium perfringens inhibitor and application thereof | |
| CN114196580A (en) | Streptomyces lavendulae Hainan variant strain and method for preparing zhongshengmycin product by using same | |
| CN114317670A (en) | Screening culture medium and preparation method and application thereof | |
| CN102604843A (en) | Preparation method of fungus fermentation product and application thereof in prevention and treatment of rice diseases | |
| Majhi | Screening of antibiotic producing Actinomycetes for antibiosis from soil of Sunsari, Nepal | |
| CN114349762B (en) | 6/6/6/6/5/5 cyclic alkaloid compounds with novel frameworks and application thereof in preparation of antibacterial drugs | |
| CN114350529B (en) | Licorice endophytic fungus for producing chalcone components and application thereof | |
| CN109575040B (en) | Compound with antibacterial activity and preparation method thereof | |
| CN109593074B (en) | Separation preparation and application of compound with antibacterial activity in fungus secondary metabolite | |
| CN107739740A (en) | A kind of preparation method and application of the Lasiodiplodins compounds in marine fungi source | |
| Mahmoud et al. | Biochemical and molecular characterization of Klebsiella species isolated from neoplastic patients under Irradiation therapy | |
| CN102993030B (en) | Benzyne compound and preparation method thereof, as well as application in control of rice pathogens |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| CB02 | Change of applicant information | ||
| CB02 | Change of applicant information |
Address after: 563000 No. 201, Dalian Road, Zunyi, Guizhou Applicant after: ZUNYI MEDICAL University Address before: 563000 No. 201, Dalian Road, Huichuan District, Zunyi City, Guizhou Province Applicant before: ZUNYI MEDICAL University |
|
| GR01 | Patent grant | ||
| GR01 | Patent grant |